New classification of gynecologic cancers
|
|
- Annabella Baker
- 5 years ago
- Views:
Transcription
1 Centre Jean Perrin Centre de Lutte contre le Cancer d'auvergne Clermont-Ferrand - France - New classification of gynecologic cancers Frédérique Penault-Llorca
2 Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer Mar 1;136(5):E
3 ENDOMETRIAL CARCINOMA
4 First of all: familial forms Familial Endometrial Carcinomas Lynch II (HNPCC) Mutations in DNA repair genes Endometrial carcinoma 15yrs earlier (46yrs old) Cumulated risk: 40 to 70% Family history should be explored for all endometrial K Screening and prophylactic hysterectomy Cowden PTEN Mutation Risk X 3 à 5 : cumulated risk: 28%
5 Endometrial carcinoma Lynch < 50 yrs Multifocal Uterine lower segment High grade endometrioid Heterogeneous tumors Non endometrioid < 60 yrs Lymphocytic stroma Invasive tumors, embolies Synchronous T ovaries/endometrium: CCC Screening by IHC MSH1, MLH2, MLH6, PMS2 when endometrial carcinoma is diagnosed in women under 60yrs regardless family history
6 Endometrial carcinoma <40yrs Endometroid G1-2 (80%) Stage I-II (90%) Good prognosis: 6% of mortality Synchronous T ovary/endometrium (13%): endometroid 16% MSI-H phenotype : worse prognosis (mortality 23% vs 6%) Don t forget the other causes: polycystic ovaries syndroma and granulosa cell tumor
7 IT WAS «ALMOST» SIMPLE
8 «ENDOCRINE» CLASSIFICATION
9 1-5% Type I hormono dependent 50 59yrs Hyperestrogeny Endometrial carcinoma Type II non hormono dependent 66 yrs (post menoposal) Absence of hyperestrogeny 5-10% 70-75%
10 Type I Endometrial carcinoma Bokhman Type II 77 to 80% Endometrioid Hyperplasia of endometrium Precursor : atypical hyperplasia 10 to 23% Serous and clear cell Atrophic endometrium precursor : EIC Intraepithelial carcinoma EIC (Bokhman, based on the pathology of Russian women in the 0 s, 0 s Other histotypes are excluded including Lynch
11 Dichotomic classification Type 1 Type 2
12 HISTO-MOLECULAR SUBTYPES OF ENDOMETRIAL CANCER Murali, Lancet Oncol 2014
13
14 TCGA endometroid carcinoma POLE (ultramuted) MSI (hypermuted) Copy number low ( endometroid ) Copy number high (Non endometroid) Log rank p = 0,02 POLE (ultramuted) MSI (hypermuted) Copy number low Copy number high ASCO 2013 Pashtan I, abstr actualisé Nature 2013;497:67-73
15 TCGA results for endometroid carcinomas POLE sub unit of ADN polymerase e => role in DNA replication, frequent mutations MSI (MLH1 promotor methylation, Lynch) KRAS, PTEN mutations Low copy number: MSS CTNNB1 mutations High copy number : P53+++ rares mutations of KRAS, PTEN [Nature 2013;497:67-73],
16 Frequency 8% 40% 28% 24% Bokman subtypes Molecular subtypes POLE Type I MSI Low copy number MSS Type II High copy number serous Histologic subtypes Grade Endometrioid I,II, III I,II, III I,II III Serous & endo Altered copy nbr Mutation rate PI3K alterations KRAS alterations P53 mut Pronostic 35% 5% 1% >90% Good Intermediate Poor
17 POLE MUTATIONS POLE : gene coding for DNA Polymerase E ENDOMETRIAL CANCER PROGNOSIS TISSUE GENOMICS EMERGING
18 Frequency 8% 40% 28% 24% Bokman subtypes Molecular subtypes POLE Type I MSI Low copy number MSS Type II High copy number serous Histologic subtypes Grade Endometrioid I,II, III I,II, III I,II III Serous & endo Altered copy nbr Mutation rate PI3K alterations KRAS alterations P53 mut Pronostic 35% 5% 1% >90% Good Intermediate Poor
19 Immunotherapy : strong rational for MSI and POLE tumors Nb élevés de néo-antignens et de Tils high levels of TILs and neoantigens
20 Endometrial Cancer (EC) Four molecular subtypes<br />(Integrated genomic, transcriptomic and proteomic characterization)
21 Parp inhibitors and endometrial carcinoma: strong rational Defect in homologous recombination in serous tumors (type2) TCGA Group 4 Similar evolution to high serous ov Ca BRCA : mutations in ~ 10% but probably underestimated Activity of Parp inhibitors in case of Pten inactivation or Arid1A alterations TCGA group 2 and 3 Leary, Current opinion Oncol 2016, Prurdle, Modern Pathol 2017
22 E N D O M E T R I A L K Not routinely performed nowadays PolE sequencing Group 1 POLE mutated IHC MMR MSH6, PMS2, MLH1, MSH2 Group 2 MSI IHC P53 Non mutated MMR Non mutated POLE mutated MSI profile P53 mut 0 or>75% Group 3 MSS P53 wild type Copy number low Group 4 P53 mutated Copy number high
23 E N D O M E T R I A L K PolE sequencing Group 1 POLE mutated IHC MMR MSH6, PMS2, MLH1, MSH2 Group 2 MSI IHC P53 Non mutated MMR Non mutated POLE mutated MSI profile P53 mut 0 or>75% Group 3 MSS P53 wild type Copy number low Immuno? Parp inh? Other? Group 4 P53 mutated Immuno? Immuno? Parp Inh? Combo Immuno-Parp? Copy number high Parp Inh?
24 Conclusion Uterine carcinoma : determination of the proper histologic subtype is of paramount importance for treatment strategies Grade 3 endometrial carcinoma of good prognosis (POLE mutation) not routine yet Emerging potential targets Familial forms: systematic LYNCH screening for tumors before 60yrs old
25 OVARIAN EPITHELIAL TUMORS
26 Ovarian cancer mortality
27 WHO, 2014 Ovarian Epithelial Tumors Serous 50% (transitional cell carcinoma) rare Endometrioid 20% Mucinous (intestinal) 15% Sero-mucinous (endocervical) rare Clear cell 5% Brenner 5% Indifferenciated 5-7%
28 Risk factors for EOC Predispositions: 5-10% Hereditary monogenic Multifactorial Susceptibilities:10-30% Hereditary multigenic Multifactorial Sporadic: 60-85% Multifactorial
29 Possible genetic context Family aggregations of ovarian cancer (frequent): - breast cancers (man-woman) / ovary BRCA genes - colon / endometrium / ovaries (Lynch) MMR genes - ovaries only BRCA & MMR + other genes... - ovarian cancers - 1 ovarian cancer <60 years Hereditary diseases with associated clinical signs (rare): associated genes Non-epithelial tumors Peutz-Jegher, Swyer, familial gonadal neoplasia, Carney... Epithelial tumors Gorlin, A.T., Maffucci, Gardner, Werner, SLF, Cowden, Bloom...
30 First of all: familial forms Genetic risk: 3 principal syndromes Ovarian cancer site specific: familial: >3 cases of OvCa, Mean age 49 yrs old, RR 40 if BRCA1 and 12% if BRCA2 BRCA1:Mutation 75% of the cases Breast/ovaries syndrome: familial: >3 cases of breast Ca and > 2 OvCa, Mean Age= 52 yrs, RR X 50%=> RR 60% if BRCA1 vs RR 30% if BRCA2 Mutation BRCA 1/2: 95% of the cases Ford et al, 1994 Dauplat et al, 1998
31 Age: Predicted BRCA1 and BRCA2 carrier probability for breast and ovarian cancer cases Age at onset (years) Breast cancer Ovarian cancer BRCA1 BRCA2 BRCA1 BRCA % 5.0% 0.6% 0.8% % 2.0% 8.2% 0.4% % 1.5% 1.8% 1.6% % 1.2% 1.3% 0.8% % 0.8% 0.1% 0.1% Among ovarian cancer cases diagnosed at 40 years, the probability of BRCA1/2 germline mutation is 8.6% Among ovarian cancer cases diagnosed at 70 years, the probability of BRCA1/2 germline mutation is 0.2%, a figure similar to general population Antoniou et al, Br J Cancer, 2004
32 Danish study in population-based series of patients with newly diagnosed ovarian cancer (MALOVA study) 10% had 1 family history of breast/ovarian cancer» Invasive epithelial ovarian cancer (N=445) BRCA mutations 5.8% (BRCA1: 22 patients; BRCA2: 5 patients) Serous Endometrioid Mucinous Clear cell Undifferentiated Other 62% 13% 10% 7% 2% 7% BRCA mutations 5.4% BRCA mutations 5.4% BRCA mutations 0% BRCA mutations 9.1% BRCA mutations 12.5% BRCA mutations 13.3% No tumours from BRCA mutation carriers were mucinous Soegaard M, et al. Clin Cancer Res 2008;14(12):
33 First of all: familial forms Genetic risk: 3 principal syndromes Lynch (HNPCC Hereditary non-polyposis colorectal carcinoma) familial: >3 cases of CRC (one before 50 yrs), endomerium, biliary tract, urinary tract, ovaries, Mean age: 45 yrs, RR 10%, Microsatellite instability: MSH1, MSH2, PMS1, PMS2, MLH1 (MSH2: RR 38 MLH1: RR20 MSH6: RR1) Other Syndromes : Peutz Jegher Syndrome: STK11 (ch19) mutation; Prevalence: 1/10.000, hamartomatous Polyposis of the digestive tract, CRC (60%), Breast (32-54%), ovaries (20%), uterus (10%), pancreas Lynch et al, 1986 Chabbert-Buffet et al, 2012
34 IT WAS «ALMOST» SIMPLE
35 Ovarian Oncogenesis Kurman 2008 Type I 25% Stade I Slow evolution Mutations BRAF, KRAS, PTEN, b catenin Precursor : Endometriosis Borderline T Endometrioid Serous low grade Mucinous Clear cell carcinoma Type II 75% > stade I Rapid evolution P53 Mutations Genetic instability De novo ut STIC High grade serous Undifferenciated carcinoma Carcinosarcoma (MMMT)
36 A dual origin? 60%? 40%? Dysplasie Tube dysplasia tubaire Dysplasie Ovarian dysplasia ovarienne Crum et al, 2010
37 Ovarian tumors linked to endometriosis Endometriosis is precursor for CCC, endometroid and seromucinous ARID 1A - ARID 1A + ARID 1A 20% of endometrioid ovarian endometrioma
38 BUT.
39 HISTO-MOLECULAR SUBTYPE OVARIAN CANCER 90% 10% Banerjee S & Kaye SB, Clin Cancer Res DIFFERENT EPITHELIAL OCs (EOCs) high-grade serous (HGSOC) low-grade serous (LGSOC) mucinous clear cell endometrioid Prat J, Virchow s Archive 2012
40 Ovarian carcinoma 5 distinct diseases HG serous LG serous mucinous Endome trioid Clear cell Frequency 70% <5% 3% 10% 5-10% Risk factor BRCA1/2?? HNPCC HNPCC+/- Precursor STIC LMP serous LMP mucinous Endome triosis Endome Triosis Mol Biol P53/BRCA BRAF KRAS PTEN HNF1b KRAS HER2 ARD1A ARD1A PIK3CA ChimioSens High Intermediate Weak High Low Prognosis Poor Intermediate Good Good Intermediate to poor
41 Banerjee S, and Kaye S B Clin Cancer Res 2013
42 Loss of expression of BAF250a* Chimioresistance MEK inhibitors? TZB? (HER2 amplification) 42 PI3K mtor? Inhibitors of ARID1A Type I ARIDIA PI3KCA ZNF217 PPP2RIA Mutation CTNNBI PTEN PIK3CA PPP2RIA Mutation Endometrioid Clear cell KRAS BRAF ERBB2 PIK3CA Mutation HER2 KRAS Mutation Mucinous TP53 mutation Cromosomal instability High-grade serous Inactivation of BRCA 1/2 (Mutation or hypermethylation) Parp Inhibitors Platinium salts Type II BRAF inhibitors TZB? Double inhibition : PI3K & MEK inhibitors fromwiegand K et al J Pathol 2011 Mc Conechy M et al J Pathol 2012
43 FOCUS ON BRCANESS IN HIGHGRADE SEROUS CARCINOMAS
44 Serous carcinomas Low grade: Extremely rare High grade: Common
45 HISTO-MOLECULAR SUBTYPE High-Grade Serous OC (HGSOC) (70% of primary EOCs) OVARIAN CANCER PROGNOSIS / PREDICTION TISSUE MORPHO + IHC + GENOMICS EMERGING Gurung A et al, Histopathology 2013 HALLMARK GENOMIC INSTABILITY DRUGS PLATINUM SALTS PARP INHIBITORS Prat J, Virchow s Archive 2012
46 Presence of a BRCA mutation Allows the possibility of a very effective treatment in case of late relapse
47 WHAT PATIENTS TO TEST?
48 ?? 3 2?
49 Only patients with a family history? Percentage of BRCA Mutation Carriers Who Lack a Family History Walsh et al 27% Family history is not a sufficient Soegaard et al 54% Malander et al 8% criterion! Risch et al 37% Alsop et al 44% Song et al 39% Between 35% to 40% of patient with BRCA1/2 Do NOT have a family history Walsh T, et al. Proc Natl Acad Sci U S A. 2011;108: ; Soegaard M, et al. Clin Cancer Rev. 2008;14: ; Malander S, et al. Eur J Cancer. 2004;40: ; Risch HA, et al. J Natl Cancer Inst. 2006;98: ; Alsop K, et al. J Clin Oncol. 2012;30: ; Song H, et al. Hum Mol Genet. 2014;23(17):
50 Only young patients? BRCA1/2 - BRCA1 + BRCA2 + Alsop et al 60 y 53 y 60 y Soegaard et al 61 y 49 y Age Risch et is al not a 56 sufficient y 51 y criterion! 57 y Malander et al 59 y 57 y Song et al 59 y 52y 57y At least 25% of pts with BRCA1/2 Mutations are older than 60 yrs Alsop K, et al. J Clin Oncol. 2012;30: ; Soegaard M, et al. Clin Cancer Rev. 2008;14: ; Risch HA, et al. J Natl Cancer Inst. 2006;98: ; Malander S, et al. Eur J Cancer. 2004;40: ; Song H, et al. Hum Mol Genet. 2014;23:
51 Only pts with a high grade serous carcinoma? Frequency of germline BRCA mutation Total population Serous Endometrioid Clear Cell Histological type (except Mucinous Alsop et al 14.1% 16.6% 8.4% 6.3% NA mucinous) is not a sufficient Risch HA et al 13.2% 18.0% 7.1% 7.1% 0% Soegaard M et al 5.8% 5.4% 5.4% 9.1% 0% criterion! Jacobi CE et al 13.9% 10.8% 0% 0% 0% Malander S et al 8% 7.6% 13.0% 12.5% 0% Alsop K, et al. J Clin Oncol 2012;30: ; Risch HA, et al. J Natl Cancer Inst 2006;98: ; Soegaard M, et al. Clin Cancer Rev. 2008;14: ; Jacobi CE, et al. Genet Med 2007;9: ; Malander S, et al. Eur J Cancer. 2004;40: ; Pennington KP et al. Clin Cancer Res. 2014;20:
52 French guidelines (st Paul de Vence) for BRCA mutation testing (2018) BRCA mutation testing must be proposed To all patients with high grade, undifferentiated, carcinosarcoma or clear cell ovarian (or primary peritoneal) serous or endometrioid cancer. Whatever the age or family history
53 How to look at BRCA mutations Germinal: hereditary family implication On blood or sputum Somatic: acquired tumor alterations no family implications test on the tumor
54 Diagnosis Oncogenetic counselling gbrca 14-20% French INCa guidelines 2017 Positive result Negative result sbrca 5-11% Positive result Negative result
55 Frequency of BRCA somatic mutations Hennessy et al TCGA network Alsop et al Population 235 unselected epithelial ovarian cancers 489 high-grade serous ovarian cancers 1001 nonmucinous ovarian cancers Frequency of somatic mutations 5% 6.3% 6% Pennington et al 390 ovarian carcinomas 7% Ledermann et al 265 high-grade, recurrent ovarian carcinomas, platinum-sensitive 7% Hennessy BT, et al. J Clin Oncol. 2010;28: ; The Cancer Genome Atlas Research Network. Nature. 2011;474: ; Alsop K, et al. J Clin Oncol. 2012;30: ; Pennington P, et al. Clin Cancer Res. 2014;20: ; Ledermann J, et al. Lancet Oncol. 2014;15:
56 Context Tumor Type: high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer Analysis of germline BRCA1/2 (blood) at the initial diagnosis of the tumor after oncogenetics consultation Analysis of somatic BRCA1/2 (the tumor): at the first platinosensitive relapse if BRCA1/2 germinal mutation negative (~7% extra positive cases) or if not tested at baseline
57 Somatic BRCA testing Requirements Adequate quantity of tumor material (FFPE) Control of pre-analytical steps (optimal quality) NGS (Next Generation Sequencing) with external quality control Timing => Results: 2 to 3 weeks Major limitations Tissue is the issue! Quantity of tissue available Quality of tissue available Complexity of NGS data analysis Validation of the results (Sanger) Turnaround time (costs if non-pooled tests) FFPE: formalin-fixed, paraffin-embedded
58 MOLECULAR TESTING ACCURACY DEPENDS UPON PATHOLOGISTS.AND SURGEONS
59 Type of samples
60 QUANTITY
61 Mc Cluggage Mod Pathol 2015 Type of samples
62
63 Initial diagnosis: OK but beware of necrosis Optimal and quick fixation Peritoneal biopsies => guidelines for surgeons 6 biopsies 5-10mm Beware of electrocoagulation
64 Examples of unsuitable samples Many samples do not have enough tumor Early discussion with surgeons or pathologists would have led to different specimens Low tumor content (post neoadjuvant) or diffuse necrosis Tiny biopsies despite huge peritoneal mets
65 Examples of unsuitable samples Many samples do not have enough tumor Early discussion with surgeons or pathologists would have led to different specimens pcr: pathological complete response Post neoadjuvant Low tumor residual content or pcr
66 Example of adequate samples Tumor content and surface area are the key! Cellularity > 20% Surgical specimen Many small biopsies with dense tumor
67 ANALYTICAL
68 NGS for BRCA1/2 Goals Exhaustive coverage of BRCA1/2 genes Acceptable sensitivity Germinal: 30X Somatic: 100 to 300X Limits BRCA1/2: large genes, no hot spots Diversity of mutations (SNP, ins/del, RGT) Quantity of material Quality of samples and design Detection of large rearrangments (10% BRCA1, 2% BRCA2) Del: deletion; ins: insertion; NGS: next generation sequencing; SNP: single-nucleotide polymorphism; RGT: rearrangement
69 POST-ANALYTICAL: INTERPRETATION
70 Clinical report Suitability of tumor sample Target analysed: examined genes (i.e. BRCA1 or BRCA2) Region of interest: the regions covered for each gene (e.g. coding region only or intronic and exonic regions) Overall results: either pathogenic/deleterious variant present or absent Mutation details (when present)
71 Clini al report ont Reference sequence Summary/interpretation: Pathogenic or likely pathogenic classification of the identified variants Non-pathogenic variants should not be reported, (laboratory may keep a record) Variants of unknown significance should be reported separately and clearly indicate the lack of sufficient clinical or biological evidence
72 CONCLUSION
73 Conclusion Ovarian carcinoma : determination of the proper histologic subtype is of paramount importance for treatment strategies (exclude metastasis for bilateral non serous tumors) Always question the pathologist in case of bilateral non serous carcinoma Specific mutations for granulosa cell tumors (FOXL2) and Sertoli cell tumors (DICER) Familial forms
74 Conclusion The spectrum of ovarian carcinoma shows heterogeneous disease with different biology and putative targets Emerging potential targets (BRCA, PIK3CA, ARID A, HER + immunotherapy With the advent of parp inhibitors, the pathologists role in the management of high grade serous tumors has changed
75 Important take home messages EVERY women with a epithelial non mucinous ovarian cancer should be tested for BRCA 1 &2 Every women <60 years with an endometrial cancer should be tested for MSI Time as come to incorporate genetics to oncology
Dall istologia alla caratterizzazione biomolecolare
Il carcinoma ovarico: approccio multidisciplinare e prospettive terapeutiche Dall istologia alla caratterizzazione biomolecolare Anna Pesci Ospedale SC Don Calabria, Negrar anna.pesci@sacrocuore.it Ovarian
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationCurrent Concept in Ovarian Carcinoma: Pathology Perspectives
Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationMolecular Subtyping of Endometrial Cancer: A ProMisE ing Change
Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change Charles Matthew Quick, M.D. Associate Professor of Pathology Director of Gynecologic Pathology University of Arkansas for Medical Sciences
More informationOvarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center
Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center Ovarian cancer is not a single disease Ovarian Epithelial Tumors: Histological Spectrum* Type Frequency Histology High-Grade
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationCase presentation 04/13/2017. Genomic/morphological classification of endometrial carcinoma
Genomic/morphological classification of endometrial carcinoma Robert A. Soslow, MD soslowr@mskcc.org architecture.about.com Case presentation 49 year old woman with vaginal bleeding Underwent endometrial
More informationof 20 to 80 and subsequently declines [2].
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
More informationBases biológicas del cáncer de ovario en el siglo XXI
Bases biológicas del cáncer de ovario en el siglo XXI Iñigo Espinosa, M.D. Clínica Universidad de Navarra Epithelial Ovarian Tumors WHO 1973-2014 Serous Mucinous Endometrioid Clear cell Transitional Squamous
More informationCase Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr
Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Professor Yong Loo Lin School of Medicine, National University
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationLYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)!
LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)! Kathryn Singh, MPH, MS, LCGC Associate Clinical Professor Assistant Director, Graduate Program in Genetic Counseling Division of Genetic and Genomic
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome
Hereditary Ovarian and Breast Cancer Syndrome C. Blake Gilks, MD Dept of Pathology Vancouver General Hospital University of British Columbia Blake.gilks@vch.ca The USCAP requires that anyone in a position
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationOvarian carcinoma classification. Robert A. Soslow, MD
Ovarian carcinoma classification Robert A. Soslow, MD soslowr@mskcc.org WHO classification Serous Mucinous Endometrioid Clear cell Transitional Squamous Mixed epithelial Undifferentiated Introduction Rationale
More informationRaccomandazioni del Genetista. Dott.ssa Raffaella Casolino - Oncologia Negrar
Raccomandazioni del Genetista Dott.ssa Raffaella Casolino - Oncologia Negrar Genetic Test and Ovarian Cancer International Recomandations for BRCA Genetic Test NCCN (National Comprehensive Cancer Network):
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationContent. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome
of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines
More informationMolecular Gynaecological Pathology
Molecular Gynaecological Pathology Simon Herrington University of Edinburgh Division of Pathology Edinburgh Cancer Research Centre Institute of Genetics and Molecular Medicine Western General Hospital
More informationLow-grade serous neoplasia. Robert A. Soslow, MD
Low-grade serous neoplasia Robert A. Soslow, MD soslowr@mskcc.org Outline Orientation Ovarian tumor overview Non serous borderline tumors Serous borderline tumors Clinical summary Morphologic description
More informationIntroduction. Why Do MSI/MMR Analysis?
Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationWhat s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden
What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden Maastricht Pathology 2018 Wednesday 20 th June Endometrioid adenocarcinoma High grade carcinomas (common)
More informationUniversal Screening for Lynch Syndrome
Universal Screening for Lynch Syndrome St. Vincent/Ameripath protocol proposal Lynch syndrome (HNPCC) 1/35 individuals with colorectal cancer has Lynch syndrome Over half individuals are >50 at time of
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationTo discuss. Predictive Value of BRCA Histology. Tumour morphology: BRCA-1. Hereditary breast-ovarian cancer (HBOC)
The role of histopathology in iden2fying gene2c condi2ons associated with gynaecological malignancies, with special a7en2on to pathological manifesta2ons of Lynch syndrome Dr Raji Ganesan Consultant Gynaecological
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationClonal evolution of human cancers
Clonal evolution of human cancers -Pathology-based microdissection and genetic analysis precisely demonstrates molecular evolution of neoplastic clones- Hiroaki Fujii, MD Ageo Medical Laboratories, Yashio
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationPatologia Molecular del Carcinoma de Ovario
Curso de Patologia Molecular XXVI Congreso Nacional de la SEAP Cadiz Patologia Molecular del Carcinoma de Ovario Jaime Prat Barcelona Ovarian Epithelial Tumors WHO 1999 and 2003 Serous Mucinous Endometrioid
More informationLYNCH-SYNDROME RELATED GYNECOLOGIC PATHOLOGY MARIA LUISA CARCANGIU M.D.
LYNCH-SYNDROME RELATED GYNECOLOGIC PATHOLOGY MARIA LUISA CARCANGIU M.D. Aldred Scott Warthin Warthin A. Heredity with reference to carcinoma. Arch Intern Med. 1913; 4:681 696 History 1913- Michigan pathologist
More informationColonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors (neoplasms) 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationObjectives. Case Study #1 1/28/14. A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice
A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice Heather Hampel, MS, CGC Associate Director, Division of Human Genetics Professor, Department of
More informationInterpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining
Stains for Tumor Classification p53 p16 WT1 HMGA2 P53 Mutations are Ubiquitous in High Grade Serous Carcinoma Source Ahmed et al Australian Ovarian Cancer Study Cancer Genome Atlas Research Network Cases
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS
ENODMETRIAL CARCINOMA: SPECIAL & NOT SO SPECIAL VARIANTS Pacific Northwest Society of Pathologists Vancouver, B.C. September 26, 2015 Teri A. Longacre, M.D. longacre@stanford.edu Stanford University, Stanford,
More informationOvarian Cancer Causes, Risk Factors, and Prevention
Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.
More informationBiology of Ovarian Cancer
Biology of Ovarian Cancer John W. Moroney, M.D. Associate Professor Department of Obstetrics and Gynecology Department of Medicine University of Chicago Pritzker School of Medicine Disclosure No conflicts
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationCase Study. Overview. Deleterious MLH1 mutation detected on sequencing 10/16/2014
The Role of Next Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Endometrial Cancer Laura J. Tafe, MD Assistant Professor of Pathology Assistant Director, Molecular Pathology Dartmouth-Hitchcock
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationGenetic Testing for Lynch Syndrome
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post-test genetic counseling is
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationYes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationBiology Response Controversies and Advances
Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER
More informationIdentification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationA Review from the Genetic Counselor s Perspective
: A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,
More informationPrior Authorization. Additional Information:
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationThe Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto
Immunohistochemical Assessment of Mismatch Repair Proteins in Endometrial Cancer: The Whys and How Terence J. Colgan, MD Head of Gynaecological Pathology, Mount Sinai Hospital, University of Toronto, Toronto.
More informationHereditary ovarian cancer
Critical Reviews in Oncology/Hematology 69 (2009) 28 44 Hereditary ovarian cancer Antonio Russo,1, Valentina Calò 1, Loredana Bruno, Sergio Rizzo, Viviana Bazan, Gaetana Di Fede Department of Surgery and
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationHereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com
Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics
GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review
More informationLynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017
1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationTumori eredofamiliari: sorveglianza di donne ad alto rischio
Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed
More informationCOLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University
COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University 1. I am a surgeon; of course I have nothing to disclose.
More informationUpdates in Gynecologic Oncology. Todd Boren, MD Gynecologic Oncologist Chattanooga s Program in Women s Oncology Sept 8 th, 2018
Updates in Gynecologic Oncology Todd Boren, MD Gynecologic Oncologist Chattanooga s Program in Women s Oncology Sept 8 th, 2018 COI I have no conflict of interest to report Endometrial Cancer: Risk Factors
More informationTumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer
TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial
More informationGenetic Determinants, Risk Assessment and Management
Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon
More informationHow common are mutations in the MSH2 gene? 1. Mutations that cause Lynch syndrome are rare found in approximately 1 in 370 individuals.
The gene is a tumor suppressor gene. Tumor suppressor genes slow down cell division, repair DNA mistakes, or tell cells when to die. When they don't work properly, cells can grow out of control, which
More informationNewton Wellesley Hospital 2013
Newton Wellesley Hospital 20 Standard 4.6 Assessment and Evaluation of Treatment Planning Endometrial Cancer Each year a physician member of the cancer committee conducts a study to ensure that diagnostic
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationThe molecular genetics of endometrial cancer
The molecular genetics of endometrial cancer Lora Hedrick Ellenson, M.D. Department of Pathology and Laboratory Medicine Weill Medical College of Cornell University Introduction Classification of endometrial
More informationHereditary Cancer Update: What do GPOs need to know?
Hereditary Cancer Update: What do GPOs need to know? Mary McCullum, RN, MSN, CON(C) Nurse Educator, Hereditary Cancer Program BC Cancer Agency October 1, 2016 Conflict of Interest Disclosure Nothing to
More informationCase 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno
Case 1 Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno SAMO Interdisciplinary Workshop on Gynecological Tumors Lucern, October
More informationBRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY
BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationCélia DeLozier-Blanchet
The Genetics Consultation in OB-GYN : Hereditary cancers Célia DeLozier-Blanchet Division of Medical Genetics, Geneva University Hospital It is probable that all cancers are genetic! genetic vs. hereditary
More informationGuidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
s on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer Francis M. Giardiello, MD, 1 John I. Allen, 2 Jennifer E. Axilbund,
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationEndometrial cancer. Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology.
Endometrial cancer Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology dr.mate.szabolcs@gmail.com Epidemiology Developing countries Cervical cancer is the most common gyn. malignant tumor
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationDIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document Molecular testing strategies for Lynch syndrome in The National Institute for Health
More informationHereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
More informationPage 1 of 8 TABLE OF CONTENTS
Page 1 of 8 TABLE OF CONTENTS Patient Evaluation and Recommendation..Page 2 Testing and Follow-up..Page 3 Genetic Counseling Referral Criteria.....Page 4-5 Patient Education..Page 6 Suggested Readings...Page
More informationOvarian Clear Cell Carcinoma
Ovarian Clear Cell Carcinoma Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine 50 year old woman with chief complaint of shortness of breath
More information